Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leading player in the biotechnology sector, is garnering attention for its innovative RNA-targeted therapies. With a market capitalization of $13.47 billion, this U.S.-based company is at the forefront of developing treatments for a range of genetic and rare diseases. Ionis provides a promising portfolio of commercial-stage products and a robust pipeline that holds significant growth potential.

**Current Market Performance**

Currently trading at $83.15, Ionis’ stock sits near the higher end of its 52-week range of $25.51 to $86.50. The stock has maintained stability, with no recent price change, emphasizing investor confidence as it hovers above its 50-day and 200-day moving averages…